ペン型注入器市場

出版：MarketsandMarkets（マーケッツアンドマーケッツ）　出版年月：2021年11月

ペン型注入器市場:製品タイプ（使い捨て、再利用可能なペン）、治療[糖尿病（インスリン、GLP-1）、成長ホルモン、骨粗鬆症、生殖能力、自己免疫疾患、がん）、エンドユーザー（病院、診療所、在宅医療）、地域別 – 2026年までの世界予測

Injection Pen Market by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region – Global Forecast to 2026

–

–

The global injection pens market is projected to reach USD 53.3 billion by 2026 from USD 37.6 billion in 2021, at a CAGR of 7.2% during the forecast period. Growing prevalence of chronic diseases, increasing number of regulatory approvals, favourable reimbursement and government support, and technological advancements in injection pens tend to drive the market. Though the market is growing, but factors like alternative drug delivery modes, poor reimbursement scenarios in developing regions and needle anxiety tend to restrain the market growth. Whereas, needle-stick injuries & misuse of injection pens tend to pose a challenge for the market. But, the opportunities for the market lie in the patent expiry of biologics and emerging markets.

Based on product, the disposable injection pen segment holds the largest share during the forecast period.
Based on type, the injection pens market is segmented into reusable and disposable injection pens. In 2020, the disposable injection pens segment accounted for the largest share of the global injection pens market. The large share of the disposable injection pens segment can be attributed to their ease of use and the presence of a built-in cartridge which eliminates the need for manually loading the cartridge, making it more convenient for patients with reduced dexterity or visual impairments.

Based on therapy, the diabetes segment holds the highest growth rate during the forecast period.
Based on therapy, the injection pens market is segmented into diabetes, growth hormone therapy, fertility, osteoporosis, autoimmune diseases, cancer, and other therapies. In 2020, the diabetes segment accounted for the largest share of the injection pens market. The large share of this segment is attributed to the high prevalence of diabetes, increasing awareness about insulin pens among diabetic patients, the rising geriatric population, increased patient support programs by companies & government for diabetes, and the growing availability of insulin pens in the market.

Based on diabetes therapy, the in GLP-1 segment holds the highest growth rate during the forecast period.
Based on type of diabetes therapy, the injection pens market for diabetes therapy is segmented into insulin and GLP-1. In 2020, the GLP-1 segment accounted for the highest growth rate of the injection pens market for diabetes therapy. The growth in the market can be attributed to the higher efficiency of GLP-1 to reduce the blood sugar levels.

Based on end user, the home-care settings segment holds the highest growth rate during the forecast period.
Based on end users, the injection pens market is segmented into home care settings and hospitals & clinics. In 2020, the home care settings segment accounted for the highest growth of the injection pens market. The growing geriatric population, ease of drug administration, increasing prevalence of chronic diseases, technological advancements, and favorable reimbursement scenarios are some of the key factors driving the growth rate of the home care settings market.

Asia Pacific is expected to grow at the highest rate in 2020
Asia Pacific is expected to grow at the highest rate in the forecast year. The rising geriatric population, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for advanced technologies, and expansion of private-sector hospitals to rural areas in various countries in the APAC are the major factors driving the growth of the injection pen market in this region.

Break of primary participants was as mentioned below:
•By Company Type – Tier 1–60%, Tier 2–30%, and Tier 3–10%
•By Designation – C-level–30%, Director-level–50%, Others–20%
•By Region – North America–45%, Europe–15%, Asia Pacific–25%, Latin America- 10%, Middle East and Africa–5%

Key players in the Injection pen market

Prominent players in the injection pens market include Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Ypsomed Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), Novartis AG (Switzerland), AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Owen Mumford (UK), Sulzer Ltd. (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Pfizer (US), Biocon Ltd. (India), Lupin Ltd. (India), Wockhardt Ltd. (India), AptarGroup, Inc. (US), and Gerresheimer AG (Germany). The other players includes Shaily Engineering Plastics Ltd. (India), Bespak Europe Ltd. (UK), SHL Medical AG (Switzerland), Emperra GmbH (Germany), Nemera France SAS, Companion Medical, Inc. (US), and Jiangsu Delfu Medical Device Co., Ltd. (China).

Research Coverage:
The report analyzes the injection pen market and aims at estimating the market size and future growth potential of this market based on various segments such as product type, therapy, end user, and region. The report also includes a product portfolio matrix of various injection pen products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
•Market Penetration: Comprehensive information on product portfolios offered by the top players in the global injection pen market. The report analyzes this market by product type, therapy, end user and region
•Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global injection pen market
•Market Development: Comprehensive information on the lucrative emerging markets by product type, therapy, end user and region
•Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global injection pen market
•Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global injection pen market.

目次

1INTRODUCTION27
1.1OBJECTIVES OF THE STUDY27
1.2MARKET DEFINITION27
1.2.1INCLUSIONS & EXCLUSIONS OF THE STUDY27
1.3MARKET SCOPE28
1.3.1MARKETS COVERED28
1.3.2YEARS CONSIDERED FOR THE STUDY29
1.3.3CURRENCY29
TABLE 1EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD29
1.4STAKEHOLDERS30
1.5SUMMARY OF CHANGES30
2RESEARCH METHODOLOGY32
2.1RESEARCH DATA32
FIGURE 1RESEARCH DESIGN32
2.1.1SECONDARY DATA33
2.1.1.1Key data from secondary sources34
2.1.2PRIMARY DATA34
FIGURE 2PRIMARY SOURCES34
2.1.2.1Key data from primary sources35
2.1.2.2Key industry insights36
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION36
FIGURE 4BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS37
2.2MARKET SIZE ESTIMATION37
FIGURE 5SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS38
FIGURE 6REVENUE SHARE ANALYSIS ILLUSTRATION: SANOFI38
FIGURE 7REVENUE ANALYSIS OF THE TOP FOUR COMPANIES:
INJECTION PENS MARKET (2020)39
FIGURE 8CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTION
PENS MARKET (2021–2026)40
FIGURE 9CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS41
FIGURE 10TOP-DOWN APPROACH41
2.3MARKET BREAKDOWN & DATA TRIANGULATION42
FIGURE 11MARKET DATA TRIANGULATION METHODOLOGY42
2.4MARKET SHARE ANALYSIS43
2.5ASSUMPTIONS FOR THE STUDY43
 
2.6RISK ASSESSMENT43
TABLE 2RISK ASSESSMENT: INJECTION PENS MARKET43
2.7LIMITATIONS44
2.7.1METHODOLOGY-RELATED LIMITATIONS44
2.7.2SCOPE-RELATED LIMITATIONS44
3EXECUTIVE SUMMARY45
FIGURE 12INJECTION PENS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)45
FIGURE 13INJECTION PENS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)46
FIGURE 14INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2021 VS. 2026 (USD MILLION)46
FIGURE 15INJECTION PENS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)47
FIGURE 16GEOGRAPHICAL SNAPSHOT OF THE INJECTION PENS MARKET48
4PREMIUM INSIGHTS49
4.1INJECTION PENS MARKET OVERVIEW49
FIGURE 17GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH49
4.2ASIA PACIFIC: INJECTION PENS MARKET, BY THERAPY AND COUNTRY (2020)50
FIGURE 18DIABETES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF
THE ASIA PACIFIC INJECTION PENS MARKET IN 202050
4.3INJECTION PENS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES51
FIGURE 19CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE INJECTION PENS MARKET DURING THE FORECAST PERIOD51
4.4INJECTION PENS MARKET, BY REGION, 2021–202652
FIGURE 20NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL
INJECTION PENS MARKET IN 202652
4.5INJECTION PENS MARKET: DEVELOPED VS. DEVELOPING MARKETS52
FIGURE 21DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING
THE FORECAST PERIOD52
5MARKET OVERVIEW53
5.1MARKET DYNAMICS53
FIGURE 22INJECTION PENS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES53
5.1.1MARKET DRIVERS54
5.1.1.1Growing prevalence of chronic diseases54
FIGURE 23NUMBER OF PEOPLE WITH CHRONIC DISEASES IN THE US,
1995–2030 (MILLION INDIVIDUALS)54
FIGURE 24ESTIMATED DIABETIC POPULATION, BY REGION,
2019 VS. 2030 VS. 2040 (MILLION)55
FIGURE 25GLOBAL CANCER INCIDENCE, 2015–2040 (MILLION)55
5.1.1.2Increasing number of regulatory approvals55
5.1.1.3Favorable reimbursement and government support56
5.1.1.4Technological advancements in injection pens56
TABLE 3MARKET DRIVERS: IMPACT ANALYSIS57
5.1.2MARKET RESTRAINTS57
5.1.2.1Preference for alternative drug delivery modes57
5.1.2.2Poor reimbursement scenario in developing countries57
5.1.2.3Needle anxiety57
TABLE 4MARKET RESTRAINTS: IMPACT ANALYSIS58
5.1.3MARKET OPPORTUNITIES58
5.1.3.1Patent expiry of biologics to drive the demand for biosimilars58
5.1.3.2Growth opportunities in emerging markets58
FIGURE 26DIABETES POPULATION IN DEVELOPING COUNTRIES,
2020 VS. 2040 (MILLION)59
TABLE 5RISING INCOME LEVELS IN EMERGING COUNTRIES59
TABLE 6MARKET OPPORTUNITIES: IMPACT ANALYSIS60
5.1.4MARKET CHALLENGES60
5.1.4.1Needlestick injuries and misuse of injection pens60
TABLE 7MARKET CHALLENGES: IMPACT ANALYSIS61
5.2VALUE CHAIN ANALYSIS61
FIGURE 27INJECTION PENS MARKET: VALUE CHAIN ANALYSIS61
5.3SUPPLY CHAIN ANALYSIS62
FIGURE 28INJECTION PENS MARKET: SUPPLY CHAIN ANALYSIS63
5.4PRICING ANALYSIS63
TABLE 8PRICING OF INJECTION PENS AVAILABLE IN THE MARKET64
5.5ECOSYSTEM MARKET MAP65
FIGURE 29INJECTION PENS MARKET: ECOSYSTEM MARKET MAP65
5.6PORTER’S FIVE FORCES ANALYSIS65
TABLE 9INJECTION PENS MARKET: PORTER’S FIVE FORCES ANALYSIS65
5.6.1INTENSITY OF COMPETITIVE RIVALRY66
5.6.2BARGAINING POWER OF SUPPLIERS66
5.6.3BARGAINING POWER OF BUYERS66
5.6.4THREAT OF SUBSTITUTES66
5.6.5THREAT OF NEW ENTRANTS67
5.7REGULATORY ANALYSIS67
5.7.1NORTH AMERICA67
5.7.1.1US67
TABLE 10US FDA: MEDICAL DEVICE CLASSIFICATION67
TABLE 11US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS68
5.7.1.2Canada68
TABLE 12CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS68
FIGURE 30CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS69
5.7.2EUROPE69
FIGURE 31EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES69
5.7.3ASIA PACIFIC70
5.7.3.1Japan70
TABLE 13JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA70
5.7.3.2China71
TABLE 14CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL71
TABLE 15CHINA: CLASSIFICATION OF MEDICAL DEVICES71
5.7.3.3India71
5.8IMPACT OF COVID-19 ON THE INJECTION PENS MARKET72
5.9PATENT ANALYSIS72
5.9.1PATENT PUBLICATION TRENDS FOR INJECTION PENS72
FIGURE 32PATENT PUBLICATION TRENDS (JANUARY 2011–SEPTEMBER 2021)73
5.9.2INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS73
FIGURE 33TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR
INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021)74
FIGURE 34TOP APPLICANT COUNTRIES/REGIONS FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021)75
5.10TECHNOLOGY ANALYSIS75
TABLE 16PEN INJECTORS CLASSIFICATION75
5.10.1KEY TECHNOLOGIES76
5.10.1.1Dose setting and needle actuation76
5.10.1.2Pen injector material76
5.10.2COMPLEMENTARY TECHNOLOGIES76
5.10.2.1In-built dose and time log76
5.10.2.2Wireless connectivity76
5.10.2.3Smartpen injectors77
5.10.2.4Smart caps and attachments77
5.10.2.5Injector temperature monitoring77
5.10.3ADJACENT TECHNOLOGIES78
5.10.3.1Autoinjectors78
5.10.3.2Insulin pumps78
6INJECTION PENS MARKET, BY TYPE79
6.1INTRODUCTION80
TABLE 17INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)80
6.2DISPOSABLE INJECTION PENS80
6.2.1HIGH PATIENT COMPLIANCE AND EASE OF HANDLING TO DRIVE
THE ADOPTION OF DISPOSABLE INJECTION PENS80
TABLE 18DISPOSABLE INJECTION PENS AVAILABLE IN THE MARKET81
TABLE 19DISPOSABLE INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)81
6.3REUSABLE INJECTION PENS82
6.3.1REUSABLE INJECTION PENS TO REGISTER THE HIGHEST GROWTH
DUE TO TECHNOLOGICAL ADVANCEMENTS82
TABLE 20REUSABLE INJECTION PENS AVAILABLE IN THE MARKET82
TABLE 21REUSABLE INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)83
7INJECTION PENS MARKET, BY THERAPY84
7.1INTRODUCTION85
TABLE 22INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)85
7.2DIABETES85
TABLE 23INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)86
TABLE 24INJECTION PENS MARKET FOR DIABETES THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)86
7.2.1INSULIN87
7.2.1.1Rising prevalence of diabetes is driving the growth of this market87
TABLE 25EXAMPLES OF INSULIN INJECTION PENS88
TABLE 26INJECTION PENS MARKET FOR INSULIN THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)88
7.2.2GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY89
7.2.2.1Strong focus of major pharmaceutical companies to introduce
GLP-1 drugs to drive market growth89
TABLE 27EXAMPLES OF GLP-1 INJECTION PENS89
TABLE 28INJECTION PENS MARKET FOR GLP-1 THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)90
7.3GROWTH HORMONE THERAPY90
7.3.1DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN
THE MARKET GROWTH90
TABLE 29EXAMPLES OF INJECTION PENS FOR GROWTH HORMONE THERAPY91
TABLE 30INJECTION PENS MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)92
7.4OSTEOPOROSIS92
7.4.1GROWING PREVALENCE OF OSTEOPOROSIS IN GERIATRIC PATIENTS AND WOMEN TO DRIVE MARKET GROWTH92
TABLE 31EXAMPLES OF INJECTION PENS FOR OSTEOPOROSIS THERAPY93
TABLE 32INJECTION PENS MARKET FOR OSTEOPOROSIS THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)94
7.5FERTILITY94
7.5.1DECREASE IN FERTILITY RATE HAS RESULTED IN THE INCREASED
USE OF INJECTION PENS94
TABLE 33EXAMPLES OF INJECTION PENS FOR FERTILITY THERAPY95
TABLE 34INJECTION PENS MARKET FOR FERTILITY THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)95
7.6CANCER96
7.6.1RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH96
TABLE 35EXAMPLES OF INJECTION PENS FOR CANCER THERAPY96
TABLE 36INJECTION PENS MARKET FOR CANCER THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)97
7.7AUTOIMMUNE DISEASES97
7.7.1DEVELOPMENTS IN THERAPIES AND DELIVERY DEVICES FOR THE TREATMENT OF MS TO BOOST THE MARKET GROWTH97
TABLE 37EXAMPLES OF INJECTION PENS FOR MULTIPLE SCLEROSIS AND
PSORIASIS THERAPY98
TABLE 38INJECTION PENS MARKET FOR AUTOIMMUNE DISEASE THERAPY,
BY COUNTRY, 2019–2026 (USD MILLION)98
7.8OTHER THERAPIES99
TABLE 39INJECTION PENS MARKET FOR OTHER THERAPIES, BY COUNTRY,
2019–2026 (USD MILLION)99
8INJECTION PENS MARKET, BY END USER100
8.1INTRODUCTION101
TABLE 40INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)101
8.2HOME CARE SETTINGS101
8.2.1HOME CARE SETTINGS ARE THE LARGEST END USERS OF INJECTION PENS101
TABLE 41INJECTION PENS MARKET FOR HOME CARE SETTINGS, BY COUNTRY,
2019–2026 (USD MILLION)102
8.3HOSPITALS & CLINICS103
8.3.1GROWING INCIDENCE OF NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES HAVE INCREASED THE DEMAND FOR INJECTION PENS103
TABLE 42INJECTION PENS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,
2019–2026 (USD MILLION)104
9INJECTION PENS MARKET, BY REGION105
9.1INTRODUCTION106
TABLE 43INJECTION PENS MARKET, BY REGION, 2019–2026 (USD MILLION)106
FIGURE 35EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH
IN THE FORECAST PERIOD107
9.2NORTH AMERICA107
FIGURE 36NORTH AMERICA: INJECTION PENS MARKET SNAPSHOT108
TABLE 44INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)108
TABLE 45NORTH AMERICA: INJECTION PENS MARKET, BY TYPE,
2019–2026 (USD MILLION)109
TABLE 46NORTH AMERICA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)109
TABLE 47NORTH AMERICA: INJECTION PENS MARKET FOR DIABETES THERAPY,
BY TYPE, 2019–2026 (USD MILLION)109
TABLE 48NORTH AMERICA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)110
9.2.1US110
9.2.1.1The US dominates the North American injection pens market110
FIGURE 37TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020)110
TABLE 49US: KEY MACROINDICATORS111
TABLE 50US: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)112
TABLE 51US: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)112
TABLE 52US: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)112
TABLE 53US: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)113
9.2.2CANADA113
9.2.2.1Unfavorable regulatory processes in Canada to restrain
the market growth113
TABLE 54CANADA: KEY MACROINDICATORS114
TABLE 55CANADA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)114
TABLE 56CANADA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)115
TABLE 57CANADA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)115
TABLE 58CANADA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)115
9.3EUROPE116
TABLE 59EUROPE: INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)116
TABLE 60EUROPE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)117
TABLE 61EUROPE: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)117
TABLE 62EUROPE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)117
TABLE 63EUROPE: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)118
9.3.1GERMANY118
9.3.1.1High diabetes expenditure and reimbursement for injection pens to drive the market in Germany118
TABLE 64GERMANY: KEY MACROINDICATORS119
TABLE 65GERMANY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)119
TABLE 66GERMANY: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)120
TABLE 67GERMANY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)120
TABLE 68GERMANY: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)120
9.3.2FRANCE121
9.3.2.1Misuse of injection pens pose a threat to the growth of this market121
TABLE 69FRANCE: KEY MACROINDICATORS121
TABLE 70FRANCE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)122
TABLE 71FRANCE: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)122
TABLE 72FRANCE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)122
TABLE 73FRANCE: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)123
9.3.3UK123
9.3.3.1NHS support and access to cost-effective injection pens are likely to drive the market in the UK123
TABLE 74UK: KEY MACROINDICATORS124
TABLE 75UK: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)124
TABLE 76UK: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)125
TABLE 77UK: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)125
TABLE 78UK: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)125
9.3.4ITALY126
9.3.4.1Regional variation in terms of coverage and benefits to hinder the market growth126
TABLE 79ITALY: KEY MACROINDICATORS126
TABLE 80ITALY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)127
TABLE 81ITALY: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)127
TABLE 82ITALY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)127
TABLE 83ITALY: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)128
9.3.5SPAIN128
9.3.5.1Supportive regulations mandating the use of safety injection pens to boost the growth of the Spanish market128
TABLE 84SPAIN: KEY MACROINDICATORS129
TABLE 85SPAIN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)129
TABLE 86SPAIN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)130
TABLE 87SPAIN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)130
TABLE 88SPAIN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)130
9.3.6BENELUX131
9.3.6.1Increasing awareness about injection pen devices to
drive market growth131
TABLE 89BENELUX: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)131
TABLE 90BENELUX: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)132
TABLE 91BENELUX: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)132
TABLE 92BENELUX: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)132
9.3.7REST OF EUROPE133
TABLE 93ROE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)133
TABLE 94ROE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)134
TABLE 95ROE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)134
TABLE 96ROE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)134
9.4ASIA PACIFIC135
FIGURE 38ASIA PACIFIC: INJECTION PENS MARKET SNAPSHOT136
TABLE 97APAC: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)137
TABLE 98APAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)137
TABLE 99APAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)137
TABLE 100APAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)138
TABLE 101APAC: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)138
9.4.1JAPAN138
9.4.1.1High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan138
TABLE 102JAPAN: KEY MACROINDICATORS139
TABLE 103JAPAN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)139
TABLE 104JAPAN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)140
TABLE 105JAPAN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)140
TABLE 106JAPAN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)140
9.4.2CHINA141
9.4.2.1Large patient population and healthcare infrastructure improvements to drive the market growth in China141
TABLE 107CHINA: KEY MACROINDICATORS141
TABLE 108CHINA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)142
TABLE 109CHINA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)142
TABLE 110CHINA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)142
TABLE 111CHINA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)143
9.4.3INDIA143
9.4.3.1Rising prevalence of obesity to drive market growth143
TABLE 112INDIA: KEY MACROINDICATORS144
TABLE 113INDIA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)144
TABLE 114INDIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)145
TABLE 115INDIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)145
TABLE 116INDIA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)145
9.4.4SOUTHEAST ASIA146
9.4.4.1Growing awareness about diabetes to drive the adoption of
injection pens146
FIGURE 39DIABETES PREVALENCE IN SOUTHEAST ASIA (2019)146
FIGURE 40HEALTHCARE EXPENDITURE (% OF GDP) IN SOUTHEAST ASIA (2018)147
FIGURE 41GERIATRIC POPULATION (% OF THE TOTAL POPULATION), 2019147
TABLE 117SOUTHEAST ASIA: INJECTION PENS MARKET, BY TYPE,
2019–2026 (USD MILLION)147
TABLE 118SOUTHEAST ASIA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)148
TABLE 119SOUTHEAST ASIA: INJECTION PENS MARKET FOR DIABETES THERAPY,
BY TYPE, 2019–2026 (USD MILLION)148
TABLE 120SOUTHEAST ASIA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)148
9.4.5REST OF APAC149
TABLE 121ROAPAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)149
TABLE 122ROAPAC: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)149
TABLE 123ROAPAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)150
TABLE 124ROAPAC: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)150
9.5LATIN AMERICA150
TABLE 125LATAM: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)151
TABLE 126LATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)151
TABLE 127LATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)151
TABLE 128LATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)152
TABLE 129LATAM: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)152
9.5.1BRAZIL152
9.5.1.1Brazil dominates the injection pens market in Latin America152
TABLE 130BRAZIL: KEY MACROINDICATORS153
TABLE 131BRAZIL: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)153
TABLE 132BRAZIL: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)154
TABLE 133BRAZIL: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)154
TABLE 134BRAZIL: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)154
9.5.2MEXICO155
9.5.2.1Increasing incidence of lifestyle-related disorders to drive
market growth in Mexico155
TABLE 135MEXICO: KEY MACROINDICATORS155
TABLE 136MEXICO: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)156
TABLE 137MEXICO: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)156
TABLE 138MEXICO: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)156
TABLE 139MEXICO: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)157
9.5.3REST OF LATIN AMERICA157
FIGURE 42HEALTH EXPENDITURE (% OF GDP) IN LATIN AMERICAN COUNTRIES, 2018157
TABLE 140ROLATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)158
TABLE 141ROLATAM: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)158
TABLE 142ROLATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)158
TABLE 143ROLATAM: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)159
9.6MIDDLE EAST & AFRICA159
9.6.1INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY TO
SUPPORT MARKET GROWTH159
TABLE 144MEA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)160
TABLE 145MEA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)160
TABLE 146MEA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)160
TABLE 147MEA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)161
10COMPETITIVE LANDSCAPE162
10.1OVERVIEW162
10.2KEY PLAYER STRATEGIES162
10.3REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS163
FIGURE 43REVENUE ANALYSIS OF THE TOP PLAYERS IN THE INJECTION PENS MARKET163
10.4MARKET SHARE ANALYSIS164
FIGURE 44INJECTION PENS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020164
10.5MARKET RANKING ANALYSIS OF OEM COMPANIES165
FIGURE 45INJECTION PENS MARKET RANKING, BY OEM COMPANY (2020)165
10.6COMPANY EVALUATION QUADRANT166
10.6.1STARS166
10.6.2EMERGING LEADERS166
10.6.3PERVASIVE PLAYERS166
10.6.4PARTICIPANTS166
FIGURE 46INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT (2020)167
10.7COMPANY EVALUATION QUADRANT FOR START-UPS168
10.7.1PROGRESSIVE COMPANIES168
10.7.2DYNAMIC COMPANIES168
10.7.3STARTING BLOCKS168
10.7.4RESPONSIVE COMPANIES168
FIGURE 47INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT
FOR START-UPS (2020)169
10.8COMPANY PRODUCT FOOTPRINT170
TABLE 148PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY TYPE170
TABLE 149PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY THERAPY171
10.9GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE INJECTION PENS MARKET173
TABLE 150GEOGRAPHIC REVENUE MIX: INJECTION PENS MARKET (2020)173
10.10COMPETITIVE SCENARIO174
10.10.1PRODUCT LAUNCHES174
TABLE 151PRODUCT LAUNCHES (JANUARY 2018–SEPTEMBER 2021)174
10.10.2OTHER DEVELOPMENTS175
TABLE 152OTHER DEVELOPMENTS (JANUARY 2018–SEPTEMBER 2021)175
 
11COMPANY PROFILES176
11.1KEY PLAYERS176
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1.1NOVO NORDISK A/S176
TABLE 153NOVO NORDISK A/S: BUSINESS OVERVIEW176
FIGURE 48NOVO NORDISK A/S: COMPANY SNAPSHOT (2020)177
11.1.2BECTON, DICKINSON AND COMPANY179
TABLE 154BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW179
FIGURE 49BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)180
11.1.3YPSOMED HOLDING AG182
TABLE 155YPSOMED HOLDING AG: BUSINESS OVERVIEW182
FIGURE 50YPSOMED HOLDING AG: COMPANY SNAPSHOT (2020)183
11.1.4SANOFI185
TABLE 156SANOFI: BUSINESS OVERVIEW185
FIGURE 51SANOFI: COMPANY SNAPSHOT (2020)186
11.1.5ELI LILLY AND COMPANY188
TABLE 157ELI LILLY AND COMPANY: BUSINESS OVERVIEW188
FIGURE 52ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)189
11.1.6MERCK KGAA191
TABLE 158MERCK KGAA: BUSINESS OVERVIEW191
FIGURE 53MERCK KGAA: COMPANY SNAPSHOT (2020)192
11.1.7ASTRAZENECA193
TABLE 159ASTRAZENECA: BUSINESS OVERVIEW193
FIGURE 54ASTRAZENECA: COMPANY SNAPSHOT (2020)194
11.1.8F. HOFFMANN-LA ROCHE LTD.196
TABLE 160F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW196
FIGURE 55F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)197
11.1.9OWEN MUMFORD198
TABLE 161OWEN MUMFORD: BUSINESS OVERVIEW198
11.1.10SULZER LTD.199
TABLE 162SULZER LTD.: BUSINESS OVERVIEW199
11.1.11SUN PHARMACEUTICAL INDUSTRIES LTD.200
TABLE 163SUN PHARMACEUTICAL INDUSTRIES LTD: BUSINESS OVERVIEW200
FIGURE 56SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020)201
11.1.12PFIZER202
TABLE 164PFIZER: BUSINESS OVERVIEW202
FIGURE 57PFIZER: COMPANY SNAPSHOT (2020)203
11.1.13BIOCON LTD.204
TABLE 165BIOCON LTD.: BUSINESS OVERVIEW204
FIGURE 58BIOCON LTD.: COMPANY SNAPSHOT (2020)205
 
11.1.14LUPIN LTD.206
TABLE 166LUPIN LTD.: BUSINESS OVERVIEW206
FIGURE 59LUPIN LTD.: COMPANY SNAPSHOT (2020)207
11.1.15WOCKHARDT LTD.208
TABLE 167WOCKHARDT LTD.: BUSINESS OVERVIEW208
FIGURE 60WOCKHARDT LTD.: COMPANY SNAPSHOT (2020)208
11.1.16APTARGROUP, INC.210
TABLE 168APTARGROUP, INC.: BUSINESS OVERVIEW210
FIGURE 61APTARGROUP, INC.: COMPANY SNAPSHOT (2020)211
11.1.17NOVARTIS AG212
TABLE 169NOVARTIS AG: BUSINESS OVERVIEW212
FIGURE 62NOVARTIS AG: COMPANY SNAPSHOT (2020)213
11.1.18GERRESHEIMER AG214
TABLE 170GERRESHEIMER AG: BUSINESS OVERVIEW214
FIGURE 63GERRESHEIMER AG: COMPANY SNAPSHOT (2020)215
11.2OTHER PLAYERS216
11.2.1SHAILY ENGINEERING PLASTICS LTD.216
TABLE 171SHAILY ENGINEERING PLASTICS LTD.: BUSINESS OVERVIEW216
11.2.2BESPAK EUROPE LTD.217
TABLE 172BESPAK EUROPE LTD.: BUSINESS OVERVIEW217
11.2.3SHL MEDICAL AG218
TABLE 173SHL MEDICAL AG: BUSINESS OVERVIEW218
11.2.4EMPERRA GMBH219
TABLE 174EMPERRA GMBH: BUSINESS OVERVIEW219
11.2.5NEMERA FRANCE SAS220
TABLE 175NEMERA FRANCE SAS: BUSINESS OVERVIEW220
11.2.6COMPANION MEDICAL, INC.221
TABLE 176COMPANION MEDICAL, INC.: BUSINESS OVERVIEW221
11.2.7JIANGSU DELFU MEDICAL DEVICE CO., LTD.222
TABLE 177JIANGSU DELFU MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW222
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12APPENDIX223
12.1DISCUSSION GUIDE223
12.2KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL227
12.3AVAILABLE CUSTOMIZATIONS229
12.4RELATED REPORTS229
12.5AUTHOR DETAILS231

お問合せフォーム